Natco Pharma announced the successful completion of United States Food and Drug Administration's (USFDA) inspection of the firm's compliance to Pharmacovigilance requirements with zero observations.

NATCO's Pharmacovigilance Department, at its Corporate Office in Hyderabad, was inspected from 30 October  2023 to 01 November 2023. The Pharmacovigilance procedures of NATCO for its products marketed globally and particularly, in USA, were inspected and found to comply with USFDA's requirements.